Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAX8 | Q06710 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 4/20 | 0.30 |
| ▸ | CA1 | P00915 | 4/20 | 0.30 |
| ▸ | CA2 | P00918 | 4/20 | 0.30 |
| ▸ | CA9 | Q16790 | 4/20 | 0.30 |
| ▸ | PRKCA | P17252 | 1/20 | 0.30 |
| ▸ | AKT1 | P31749 | 1/20 | 0.30 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13381106 | 0.86 | LGALS9 (0.31) | — | |
| SCHEMBL13381075 | 0.79 | CA1 (0.37) | CA12CA1CA2CA9PRKCA | |
| SCHEMBL13381107 | 0.79 | SERPINC1 (0.30) | — | |
| SCHEMBL13381076 | 0.78 | CA1 (0.36) | CA12CA1CA2CA9 | |
| SCHEMBL17269437 | 0.77 | CA12 (0.32) | CA12CA1CA2CA9 | |
| SCHEMBL13381081 | 0.75 | PTPN1 (0.38) | CA12CA1CA2CA9 | |
| SCHEMBL13381027 | 0.75 | PTPN1 (0.33) | — | |
| SCHEMBL13381078 | 0.72 | LGALS8 (0.35) | PAX8CA12CA1CA2CA9 | |
| SCHEMBL13381064 | 0.71 | NT5E (0.36) | CA12CA1CA2CA9 | |
| SCHEMBL13381069 | 0.70 | TNF (0.35) | CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100081708-A1 | ANTICOAGULANT COMPOUNDS | ENDOTIS PHARMA (FR) | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081708-A1 | ANTICOAGULANT COMPOUNDS | SERPINC1, F2, FUT5 | PAX8 4822/4885CA12 119/4885CA1 435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.